SHANGHAI KAIBAO PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.03 CNY | +0.17% |
|
+4.69% | -9.32% |
| Sales 2022 | 1.12B 154M 211M | Sales 2023 | 1.59B 220M 301M | Capitalization | 6.96B 960M 1.31B |
|---|---|---|---|---|---|
| Net income 2022 | 191M 26.36M 36.04M | Net income 2023 | 328M 45.27M 61.89M | EV / Sales 2022 | 6.79 x |
| Net cash position 2022 | 831M 115M 157M | Net cash position 2023 | 752M 104M 142M | EV / Sales 2023 | 3.89 x |
| P/E ratio 2022 |
44.2
x | P/E ratio 2023 |
21.2
x | Employees | 1,380 |
| Yield 2022 |
0.74% | Yield 2023 |
-
| Free-Float | 53.34% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.17% | ||
| 1 week | +4.69% | ||
| Current month | -1.47% | ||
| 1 month | -0.66% | ||
| 3 months | -2.90% | ||
| 6 months | -11.84% | ||
| Current year | -9.32% |
1 week
5.75
6.07
1 month
5.586.25
Current year
5.256.89
1 year
5.258.38
3 years
4.1812.88
5 years
3.7012.88
10 years
3.7019.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Bin Zhou
CEO | Chief Executive Officer | 46 | 17-11-09 |
Dong Sheng Xue
CHM | Chairman | 54 | - |
Li Wang Ren
DFI | Director of Finance/CFO | 54 | 18-10-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jing Wei Mu
CHM | Chairman | 45 | - |
Li Wang Ren
DFI | Director of Finance/CFO | 54 | 18-10-24 |
Zu Guang Ye
BRD | Director/Board Member | 77 | 20-12-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6.03 | +0.17% | 19,758,990 |
| 24-04-25 | 6.02 | +1.35% | 12,777,150 |
| 24-04-24 | 5.94 | +0.17% | 8,763,273 |
| 24-04-23 | 5.93 | +0.51% | 12,292,280 |
| 24-04-22 | 5.9 | +2.43% | 14,654,770 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Shanghai Kaibao Pharmaceutical CO.,Ltd. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent drugs. The Company's main product is Tanreqing injection, which is used for treatment of upper respiratory tract infections, such as cold and pneumonia. The Company's products include injections, tablets, capsules, granules, vinum and pills, among others. The Company distributes its products in domestic markets.
Sector
Pharmaceuticals
Calendar
2024-06-05
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.32% | 870M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 300039 Stock
